Skip to main content

Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents

NEW YORK – Natera said on Wednesday that it has sued Inivata and its wholly owned subsidiary of the same name for alleged infringement of two of its patents.

In its complaint, filed in the US District Court for the District of Delaware on Wednesday, Natera said Inivata infringes its US Patent Nos. 10,262,755, titled "Detecting cancer mutations and aneuploidy in chromosomal segments," and 10,597,709, titled "Methods for simultaneous amplification of target loci," which it said protect intellectual property in the areas of cancer personalized monitoring and molecular residual disease testing.

Natera said Inivata infringes these patents by selling, manufacturing, and using various oncology products, including its InVision First-Lung test, which it launched in the US last summer through a partnership with NeoGenomics.

The company is asking for a jury trial, judgment that Inivitata has infringed the patents, an injunction against the company, as well as monetary damages.

"Natera has a significant portfolio of early intellectual property in the field of cell-free DNA analysis, and will vigorously defend its IP to support continued innovation in this field," Kevin Johnson, a lawyer with Quinn Emanuel Urquhart & Sullivan who is representing Natera in this matter, said in a statement.